Agile Therapeutics (AGRX)
(Delayed Data from OTC)
$1.43 USD
-0.01 (-0.69%)
Updated Jul 9, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
AGRX 1.43 -0.01(-0.69%)
Will AGRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AGRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGRX
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
AGRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?
Other News for AGRX
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics Merges with Insud Pharma Subsidiary
Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M
Agile Therapeutics to be acquired by Insud Pharma for $1.52 per share in cash
Agile Therapeutics: Q1 Earnings Snapshot